Companies: 10,795·Total market cap: $144.5T
Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRMLNASDAQHealthcare
$47.98
+$0.00(+0.00%)
Market Cap$1.2B
P/E Ratio—
52W High$48.27
52W Low$11.56
SEC Filings

Tourmaline Bio, Inc. (TRML) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001827506 · TRML · NASDAQ · as of Jun 8, 2026

Filing snapshot

346
Total Filings
EFFECT
Latest Form
2025-11-14
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001827506 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-03-13
Fiscal Year End
Mar 13, 2025
Accession No.
0001827506-25-000027
Primary Document
trml-20241231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001827506 · Accession 0001827506-25-000027

Latest Key Filings

10-QQuarterly Report
10-Q
2025-08-13
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2025-10-28Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
EFFECTEFFECT
EFFECT
2025-11-14
View
EFFECTEFFECT
EFFECT
2025-11-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-14
View
15-12G15-12G
FORM 15-12G
2025-11-07
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
S-8 POSS-8 POS
S-8 POS
2025-10-28
View
POS AMPOS AM
POS AM
2025-10-28
View
POS AMPOS AM
POS AM
2025-10-28
View
8-KCurrent Report
FORM 8-K
2025-10-28
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2025-10-28
View
Showing 1–15 of 228 filingsForm 4 / 144 hidden· 346 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001827506  |  Exchange: NASDAQ · Healthcare

Tourmaline Bio, Inc. (NASDAQ: TRML) has submitted 346 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001827506, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Tourmaline Bio, Inc.'s most comprehensive regulatory disclosure. The most recent Tourmaline Bio, Inc. 10-K was filed on 2025-03-13 for fiscal year ending 2025. Historical TRML 10-K annual reports are available from 2020 through 2025.

Investors researching Tourmaline Bio, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
TERN SEC Filings →DNTH SEC Filings →RLAY SEC Filings →ELVN SEC Filings →SNDX SEC Filings →IMTX SEC Filings →WVE SEC Filings →AMLX SEC Filings →
→ TRML Financials→ TRML Earnings→ TRML Insider Trades

Frequently Asked Questions

TRML SEC Filings · 8 questions

Tourmaline Bio, Inc. (TRML) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 346 filings and access original documents at no cost. Tourmaline Bio, Inc.'s CIK is 0001827506.

TRML SEC filingsTourmaline Bio, Inc. SEC documentsfind TRML 10-K